secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001193125-25-125071
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva prices $2.3B multi-tranche senior notes offering to refinance existing debt
--------------------------------------------------------------------------------

- Upsized offering from $2B to ~$2.3B equivalent across three tranches.
- €1B 4.125% due 2031 (priced 99.349%), $500M 6.000% due 2032 (99.256%), $700M 5.750% due 2030 (99.418%).
- Settlement expected May 28, 2025, subject to customary closing conditions.
- Proceeds to fund tender offers for existing notes with coupons 3.15%-8.125% maturing 2026-2031.
- Net proceeds may also be used for debt repayment at maturity, tender, or redemption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312525125071/0001193125-25-125071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312525125071/d929611d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-125071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer